688253 Innovita Biological Technology
- 42.20
- 0.000.00%
Innovita Biological Technology News
Innote (688253.SH) will pay 0.4 yuan per share in 2023. The stock registration date is June 5
Innote (688253.SH) issued an announcement. The company will implement the 2023 annual equity distribution, and each share will be distributed to discover...
Innovita Biological Technology's (SHSE:688253) Strong Earnings Are Of Good Quality
Innovita Biological Technology Co., Ltd.'s (SHSE:688253) strong earnings report was rewarded with a positive stock price move. We have done some analysis, and we found several positive factors beyond
Innote (688253.SH) announced its 2023 annual results, with net profit of 174 million yuan, an increase of 15.44%
Innote (688253.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 4...
Innovita Biological Technology Co., Ltd.'s (SHSE:688253) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Most readers would already be aware that Innovita Biological Technology's (SHSE:688253) stock increased significantly by 47% over the past three months. We wonder if and what role the company's fina
Innote (688253.SH): Key marketing products this year are still chromatographic products, and Jiulian products are dominated by steady growth
Gelonghui March 5 | Innote (688253.SH) disclosed an investor relations activity record table showing that this year's key marketing products are still chromatographic products, and Jiulian products are mainly growing steadily. Molecular products are expected to be launched soon. The products are positioned as routine testing items in hospitalization scenarios, and no separate equipment is required. As molecular platform technology matures, molecular POCT products are also the company's long-term plans.
Innote (688253.SH): At present, the product has basically achieved automated production capacity sufficient to meet sales needs
Gelonghui, March 5, 丨 Innote (688253.SH) disclosed an investor relations activity record sheet showing that at present, the company's products have basically been automated, and multiple automated production lines have been set up, and production capacity is sufficient to meet sales needs.
Some shareholders of Innote (688253.SH) reduced their holdings by a total of about 3.63%, and the reduction period of their holdings expired
Innote (688253.SH) issued an announcement. The company received a notification letter on March 1, 2024, as of 20...
Innote (688253.SH): Investment in the international market will be further increased in 2024
Glonghui, March 1 | Innote (688253.SH) recently said during a survey reception from institutional investors that in the international market, the company's goal is to use the international market as the second engine for the company's business development. In 2023, the company will use Thailand as a key market development in Southeast Asia. Judging from current progress, the market feedback on the specialized marketing strategy in the Thai market is very good. In 2024, the company will further increase its investment in the international market, strategically develop locally in the Southeast Asian market, and actively deploy in the European and American markets. Especially in the European market, standards for manufacturers after the new IVDR policy
Innote (688253.SH): Currently, the company has self-test products under development and is actively preparing for application
Glonghui, March 1 | Innote (688253.SH) recently said during a survey reception from institutional investors that in addition to COVID-19 products, the company currently has self-testing products under development and is actively preparing to apply. Judging from the international market, self-testing products are still very encouraged. In the future, if the company's self-test products are approved, the promotion of the company's self-test products will have a certain advantage, depending on the high market popularity established by the company's products such as the trifecta test kit for influenza A, B, and Mycoplasma pneumoniae antigen.
Subdued Growth No Barrier To Innovita Biological Technology Co., Ltd. (SHSE:688253) With Shares Advancing 26%
Innovita Biological Technology Co., Ltd. (SHSE:688253) shareholders are no doubt pleased to see that the share price has bounced 26% in the last month, although it is still struggling to make up recen
Innote (688253.SH) performance report: 2023 net profit of 175 million yuan increased 15.95% year-on-year
Glonghui, Feb. 22 | Innote (688253.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved total operating revenue of 47,80181,000 yuan, an increase of 7.03% over the previous year; net profit attributable to the owners of the parent company was 17.4714,600 yuan, an increase of 15.95% year on year. At the end of the reporting period, the company's total assets were 206.82448 million yuan, an increase of 6.47% over the beginning of the reporting period; owners' equity attributable to the parent company was 184,467.1 million yuan, an increase of 9.19% over the beginning of the reporting period.
Innovita Biological Technology (SHSE:688253) May Have Issues Allocating Its Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Firstly, we'll want to see a proven return on capital employ
Innote (688253.SH) and the Chief Financial Officer received a warning letter from the Beijing Securities Regulatory Bureau
Zhitong Finance App News, Innote (688253.SH) announced that the company recently received the “Decision on Measures Issuing Warning Letters against Beijing Inuote Biotechnology Co., Ltd. and Zhao Xiujuan” (“Warning Letter”) issued by the Beijing Regulatory Bureau (“Beijing Securities Regulatory Bureau”) of the China Securities Regulatory Commission. After investigation, the company had the following irregularities: 1. The management of raised funds was not regulated. The cash management balance of the company's fund-raising special account from September 2022 to March 2023 repeatedly exceeded the authorized use limit of the company, exceeding the authorized limit by up to 29,196 million yuan. 2. Fund-raising
Innote (688253.SH): The 2022 respiratory series's revenue for the non-COVID-19 series was 117 million yuan, and the gross margin was about 80%
On December 26, GLONGHUI (688253.SH) said on the investor interactive platform that the company's 2022 respiratory system's revenue for the non-COVID-19 series was 117.136,900 yuan, and the gross margin was around 80%.
Innotek (688253.SH) plans to commit 20 million yuan to establish a private equity fund Hongchuang Haihe to focus on unlisted companies in the medical and health sector
Innotek (688253.SH) issued an announcement to explore the company using the investment experience and resources of professional investment institutions...
Sequoia Zhisheng, the majority shareholder of Innotek (688253.SH), reduced its holdings of the company by 1.5983% in total
Innotek (688253.SH) announced that the company's shareholders, Ningbo Meishan Bonded Port Zone Sequoia Zhisheng Equity Investment Partnership...
Innotek (688253.SH): Plans to subscribe for private equity fund shares for 5 million yuan
On December 1, Glonghui (688253.SH) announced that Jingda Guangyuan, a wholly-owned subsidiary of the company, plans to sign a “partnership agreement” as a limited partner with Beijing Yuanming Venture Consulting Partnership (Limited Partnership) and other partners to pledge additional partnership shares for private equity fund Yuansheng Beijing Angel Phase II. Yuansheng Beijing Angel Phase II will focus on the medical and health sector in China and invest in unlisted companies belonging to such fields. The company plans to pledge an investment of RMB 500 million with its own funds. The investment ratio is to account for 4.42% of the total pledged investment amount of the fund, and actually sign “
Innotek (688253.SH): The purchased cash management products are financial products or deposit products with high security, capital protection requirements, and good liquidity
On November 30, Innotek (688253.SH) stated on the investor interactive platform that the cash management products purchased by the company were wealth management products or deposit products (including but not limited to agreed deposits, notified deposits, structured deposits, time deposits, large deposit books, etc.) with high security, capital protection requirements, and good liquidity.
Innotek (688253.SH) shareholder Suzhou Xinjian Yuan reduced its holdings by 77,400 shares
Innotek (688253.SH) announced that the company's shareholder Suzhou Industrial Park Xinjian Yuan Phase II Venture Capital Enterprise (Limited...
Guolian Securities: Respiratory infectious diseases combined with high incidence seasons are optimistic about investment opportunities in the diagnosis and treatment industry chain
Vaccines are the most effective means of preventing infectious diseases, and the high incidence of influenza is expected to accelerate the release of demand for vaccination.
Analysis
Price Target
No Data
